Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.

An Artificial Intelligence to Identify Who Can Benefit from Lung cancer Immunotherapy

Lung cancer is often aggressive, making it difficult to detect while in the early stages. It does not present any noticeable symptoms, either. Targeted therapy is the best option that will ensure positive outcomes for patients with this disease. However, before administering immunotherapy, doctors need to determine which patients can benefit from this option.

For favorable outcomes for lung cancer patients, physicians have to tailor treatment for each patient. This can be tricky, especially if they don’t know who will benefit from a particular treatment. It may also be difficult for oncologists to determine how newer treatment options like immunotherapy will benefit an individual.

Immunotherapy is a cancer treatment that enhances the body’s immune response to fight cancer tumors. Scientists have developed an artificial intelligence (AI) model to help healthcare professionals identify lung cancer patients who can benefit from immunotherapy.

According to their findings;

  • The new model can help both doctors and patients decide on the best therapy for their type of lung cancer. This will also minimize unnecessary expenses incurred during immunotherapy.
  • It was developed from other findings that succeeded in identifying the signs that spotted cancerous tumors that responded to treatment.
  • They discovered that textural change could effectively predict if treatment is working.
  • The research team used data from CT scans from patients an set up a mathematical method that helped to identify the texture and other changes in the size of the tumor. They then exposed them to two or three cycles of immunotherapy.
  • They identified patterns in patients that indicated that specific changes in tumors were connected to a positive response to immunotherapy with high survival rates.

Previous studies had suggested that tumor size could conclusively indicate whether or not a treatment approach was working in a patient. But this may not be accurate since a nodule can increase in size after therapy due to a different reason such as a broken vessel within the tumor. The new artificial intelligence model has accurately shown that lung tumors with noticeable changes in their texture can respond to immunotherapy with the best patient outcomes.

More Choice Cancer Care Centers